Livtencity Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11684632 TAKEDA PHARMS USA Maribavir isomers, compositions, methods of making and methods of using
Jan, 2032

(7 years from now)



Livtencity is a drug owned by Takeda Pharmaceuticals Usa Inc. It is used for treating post-transplant cytomegalovirus (CMV) infection/disease refractory to other antiviral treatments in stem cell, kidney, or liver transplant recipients. Livtencity uses Maribavir as an active ingredient. Livtencity was launched by Takeda Pharms Usa in 2021. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 04, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 23, 2026
Orphan Drug Exclusivity(ODE-388) Nov 23, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using MARIBAVIR ingredient

NCE-1 date: 23 November, 2025

Market Authorisation Date: 23 November, 2021

Treatment: Treatment of patients with post-transplant cytomegalovirus (cmv) infection/disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet, where the patient is a stem cell, ...

Dosage: TABLET

More Information on Dosage

LIVTENCITY family patents

Family Patents